Ocugen (OCGN) Raises $20M in Registered Direct Offering with Warrants

Ocugen, Inc. entered into agreements to sell 20,000,000 shares of common stock at $1.00 per share and accompanying warrants to purchase up to 20,000,000 shares.

Rhea-AI Filing Summary

Ocugen, Inc. entered into agreements to sell 20,000,000 shares of common stock at $1.00 per share and accompanying warrants to purchase up to 20,000,000 shares. The financing is structured as a registered direct offering made under the company's effective Form S-3 shelf registration and is expected to generate approximately $20.0 million in gross proceeds before fees and expenses.

The Warrants carry an exercise price of $1.50, are exercisable immediately, and expire two years after issuance; they are callable by the company if the volume-weighted average price exceeds $2.50 for five of a trailing 30 trading day period. The investor agreed to a 90-day lock-up on resale of the securities. Noble Capital Markets is acting as sole placement agent and will receive a 5.5% cash fee plus reimbursement of up to $65,000 of expenses.

Positive

• The Offering is expected to generate approximately $20.0 million in gross proceeds before fees and expenses.
• The transaction is being conducted under the company’s effective Form S-3 shelf registration, enabling a registered direct offering.
• The investor agreed to a 90-day lock-up restricting resale of securities acquired in the Offering.
• Warrants are exercisable immediately, providing potential for the company to receive additional proceeds if exercised.

Negative

• The Offering includes issuance of 20,000,000 shares plus warrants to purchase up to 20,000,000 additional shares, representing significant potential dilution.
• Warrants carry an exercise price of $1.50, and are exercisable immediately, which could dilute existing shareholders if exercised.
• The company will pay Noble Capital Markets a 5.5% cash fee of aggregate proceeds and reimburse up to $65,000 in expenses, reducing net proceeds.
• Warrants expire in two years, creating a defined window for potential dilution and capitalization changes.

Insights

Securities/Financial Analyst

TL;DR: Ocugen completed a $20M registered direct financing with immediate warrants, providing near-term cash but issuing substantial dilution potential.

The agreement raises roughly $20.0 million in gross proceeds through the sale of 20 million shares and 20 million warrants. The warrants are exercisable immediately at $1.50 and expire in two years, giving the investor optionality that could convert to equity quickly. Placement agent compensation of 5.5% and up to $65,000 in reimbursed expenses will reduce net proceeds. From an investor-impact perspective, the transaction delivers liquidity to the company while creating near-term dilution and potential downward pressure on share count if warrants are exercised.

Corporate Finance Specialist

TL;DR: The financing uses a registered direct structure under an effective S-3, enabling faster execution and immediate exercisability of warrants.

The placement under the existing Form S-3 permits a streamlined registered sale and immediate issuance of tradable securities. The investor's 90-day lock-up limits immediate secondary selling, and the company's call feature on the warrants $2.50 for specified days) provides an exit mechanism to limit long-term overhang. Material items include the 2-year warrant term and the $1.50 exercise price; collectively these terms affect potential future dilution and capitalization modeling. Overall, the transaction is a routine capital raise with mixed implications: immediate funding but meaningful potential dilution.

8-K Event Classification

3 items: 1.01, 7.01, 9.01

3 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Ocugen (OCGN) announce in this 8-K?

The company announced a registered direct Offering to sell 20,000,000 shares and accompanying warrants to purchase up to 20,000,000 shares, expected to raise about $20.0 million in gross proceeds.

What are the key terms of the warrants in the Ocugen Offering?

The Warrants have an exercise price of $1.50, are exercisable immediately upon issuance, and expire two years from issuance; they are callable by Ocugen if VWAP exceeds $2.50 for five of a trailing 30 trading day period.

Who is the placement agent and what fees are payable?

Noble Capital Markets is the sole placement agent and will receive an aggregate cash fee of 5.5% of aggregate proceeds and reimbursement of up to $65,000 in expenses.

Are there resale restrictions on the securities sold in the Offering?

Yes, the investor agreed to a 90-day lock-up during which it will not sell or transfer securities acquired in the Offering, including shares issuable upon exercise of the Warrants.

Under what registration is the Offering being made?

The Offering is being made pursuant to the company’s effective Form S-3 shelf registration (File No. 333-278774) and related prospectus and prospectus supplement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/11/2025 - 08:35 AM Learn about SEC filing dates

false 0001372299 0001372299 2025-08-08 2025-08-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15 (d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 8, 2025

OCUGEN, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-36751		04-3522315
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

11 Great Valley Parkway

Malvern, Pennsylvania 19355

(484) 328-4701

(Addresses, including zip code, and telephone numbers, including area code, of principal executive offices)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value per share		OCGN		The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01. Entry into a Material Definitive Agreement.

On August 8, 2025, Ocugen, Inc. (the “Company”) entered into a Securities Purchase Agreement with an institutional investor (the “Securities Purchase Agreement”) relating to the issuance of 20,000,000 shares of the Company’s common stock, par value of $0.01 per share (the “Common Stock”) and warrants to purchase up to an aggregate of 20,000,000 shares of Common Stock (the “Warrants”), to such investor at a purchase price of $1.00 per share and accompanying warrants in a registered direct offering (the “Offering”). The Warrants have an exercise price of $1.50 per share, is exercisable immediately upon issuance and will expire two (2) years following the date of issuance. The Warrants are callable by the Company when the volume weighted average price of the Common Stock exceeds $2.50 per share for at least five of a trailing 30 trading day period. 

In connection with the Offering, the investor agreed to lock-up restrictions with the Company whereby it will not sell or transfer any securities acquired in the Offering, including the shares of Common Stock issuable upon exercise of the Warrants, for a period of 90 days following the closing of the Offering.

The Company also entered into a Placement Agency Agreement with Noble Capital Markets, Inc. (“Noble”) (the “Placement Agency Agreement,” and together with the Securities Purchase Agreement, the “Agreements”), who is acting as the sole placement agent for the Offering.

The gross proceeds from the Offering will be approximately $20.0 million, before paying the placement agent fees and other estimated offering expenses. The Offering is being made pursuant to the shelf registration statement on Form S-3 (File No. 333-278774) previously filed by the Company with the Securities and Exchange Commission (the “SEC”) on April 18, 2024 and declared effective on May 1, 2024. The Offering is made only by means of a prospectus forming a part of the effective registration statement and a prospectus supplement relating to the Offering.

In connection with the Placement Agency Agreement, the Company agreed to pay Noble an aggregate cash fee of 5.5% of the aggregate proceeds raised from the sale and issuance of the shares of Common Stock and accompanying Warrants. Pursuant to the Placement Agency Agreement, the Company also agreed to reimburse Noble up to $65,000 for its expenses.

The form of Warrant is filed as Exhibit 4.1 to this Current Report on Form 8-K. The Security Purchase Agreement is filed as Exhibit 10.1 to this Current Report on Form 8-K. The Placement Agency Agreement is filed as Exhibit 10.2 to this Current Report on Form 8-K. The foregoing description of the respective terms of the Agreements and Warrant are not intended to be complete and is qualified in its entirety by reference to each such exhibit. A copy of the opinion of Goodwin Procter LLP relating to the legality of the issuance and sale of the shares in the Offering is filed as Exhibit 5.1 to this Current Report on Form 8-K. 

Item 7.01. Regulation FD Disclosure.

On August 8, 2025, the Company issued a press release announcing the Offering. The press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Current Report on Form 8-K under Item 7.01, including the attached Exhibit 99.1, is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information contained in this Current Report on Form 8-K under Item 7.01, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or any filing under the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
4.1*	Form of Warrant.
5.1*	Opinion of Goodwin Procter LLP.
10.1*	Form of Securities Purchase Agreement dated August 8, 2025.
10.2*	Placement Agency Agreement dated August 8, 2025.
23.1*	Consent of Goodwin Procter LLP (included in Exhibit 5.1).
99.1	Press Release of the Company dated August 8, 2025.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

*Filed herewith.

SIGNATURES

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Ocugen, Inc.
Date: August 11, 2025
	By:	/s/ Shankar Musunuri
	Name:	Shankar Musunuri
	Title:	Chairman, Chief Executive Officer, & Co-Founder